 |
| Birla Group |
“We are by the side of a nascent stage in our three verticals — Birla Kerala Vaidyashala, Evolve Med Spa and Birla Life Science and Research. We are eager to complete Rs 200—300 crore revenue in subsequently 2—3 years through our artifact and presence spreading out,” Birla Welln ess & Healthcare Managing Director and first in command, Mr N Venkat thought.
He thought the firm’s revenue is likely to be by the side of Rs 35 crore by FY 11.
The company is looking by the side of large sales in both on the counter (OTC) ayurvedic and ethical products and spreading out of its put in storage brand — Rebirth — in Tier II and III cities, he thought.
Under Birla Life Science and Research, the company is planning to raise its OTC ayurvedic products to eight from the give to three by FY 12.
“These products will be to be had through our all India distribution net as contrary to its current presence in solitary five states,” he thought.
Similarly, the company is planning to increase in intensity its ethical products (that needs doctor’s prescription), to 30 from the give to 12 by FY 12 across the terrain, he added.
While, Rebirth will witness other 15 food by FY 12 to the already existing 14 food with the aim of houses its brands like Chant, Nutrinext and Birlaveda, he thought. - PTI